Setting new standards in information exchange for the pharmaceutical and biotech industry
FDA Accepts Investigational New Drug Application for a Cancer Vaccine Developed by Neon Therapeutics
July 28, 2016
We are pleased to hear Neon Therapeutics, founded by Immuno-Oncology 360° keynote and MD Anderson Immunology Chair, Dr James Allison, has received the FDA’s acceptance of their IND application for their lead cancer vaccine program NEO-PV-01.
Neon Therapeutics recently shared data this month at IO360°’s Rational Combinations conference in New York on how they are developing further treatment modalities including next-generation vaccines and T-cell therapies targeting both personalized as well as shared neoantigens. The FDA’s acceptance of the IND enables Neon Therapeutics to initiate their first clinical trial investigating the combination of a NEO-PV-01 with BMS’ Nivolumab in advanced melanoma, NSCLC and bladder cancer. The trial is expected to begin this year.
Dr James Allison will be delivering a keynote address on Immune Checkpoint Blockade in Cancer Therapies: New Insights and Opportunities for Cures at the 3rd Annual Immuno-Oncology 360° program taking place January 31- February 3rd, 2017 in NYC.
To read the full press release: http://www.businesswire.com/
news/home/20160729005446/en/ Neon-Therapeutics-Announces- FDA-Acceptance- Investigational-Drug
To learn more about the 3rd Annual Immuno-Oncology 360° conference visit: http://
theconferenceforum.org/ conferences/immuno-oncology- 360/overview/